Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma

Technology appraisal guidance
Reference number: TA269
Published: 12 December 2012
Last updated: 01 January 2015

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib: Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO)
02 November 2012
(252.53 Kb 13 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 29 October 2012